Breakthrough Clinical Data on Nectin-4 ADC Targeted Therapy for Cervical Cancer Revealed

In a recent report presented at the Annual Meeting of the Society of Gynecologic Oncology (SGO), Mabwell Biotechnology unveiled groundbreaking clinical data on their targeted therapy, Nectin-4 ADC, for the treatment of cervical cancer. This significant development promises to address the unmet clinical needs of patients with recurrent or metastatic cervical cancer, potentially revolutionizing their treatment options. Let's delve into the details of this exciting breakthrough.

Nectin-4 ADC, a targeted therapy developed by Mabwell Biotechnology, has emerged as the world's first drug of its kind to report clinical data specifically for cervical cancer. The clinical study, led by Professor Jian Zhang from Fudan University Affiliated Tumor Hospital, was a multicenter, open-label, Phase I/II trial that assessed the efficacy and safety of Nectin-4 ADC in patients with recurrent or metastatic cervical cancer.

The study enrolled 40 patients who had previously received platinum-based chemotherapy combined with or without pembrolizumab and progressed to no more than the second-line systemic treatment. Patients received intravenous infusions of 1.25mg/kg of Nectin-4 ADC on days 1, 8, and 15 of a 28-day cycle until disease progression, intolerable adverse reactions, death, or study withdrawal.

The results of the study were met with high acclaim from experts at the conference. Among the evaluated patients, the objective response rate (ORR) and disease control rate (DCR) were 40.54% and 89.19%, respectively. Notably, one patient achieved complete remission, while 14 patients experienced partial remission. The median progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were yet to be reached.

Within the subset of patients with Nectin-4 expression (detected in 89.67% of patients) and Nectin-4 3+ tumor cell staining intensity (detected in 67.82% of patients), the ORR and DCR were 50.00% and 92.31%, respectively. Among patients previously treated with platinum-based chemotherapy and immune checkpoint inhibitors, the ORR and DCR were 38.10% and 85.71%.

Regarding safety, 92.50% of patients experienced treatment-related adverse events, with the most common being neutropenia (40.00%), rash (17.50%), and gamma-glutamyl transferase increased (12.50%). No treatment-related deaths were reported.

The clinical data presented by Mabwell Biotechnology on Nectin-4 ADC for the treatment of cervical cancer demonstrate promising efficacy and manageable safety profiles. This innovative targeted therapy holds tremendous potential in meeting the unmet needs of patients with recurrent or metastatic cervical cancer. With further clinical research, Nectin-4 ADC may emerge as a groundbreaking treatment option, providing hope and improved outcomes for patients worldwide.